z-logo
open-access-imgOpen Access
OT ‐1 mice display minimal upper genital tract pathology following primary intravaginal C hlamydia muridarum infection
Author(s) -
Manam Srikanth,
Nicholson Bruce J.,
Murthy Ashlesh K.
Publication year - 2013
Publication title -
pathogens and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.983
H-Index - 105
ISSN - 2049-632X
DOI - 10.1111/2049-632x.12032
Subject(s) - chlamydia , biology , chlamydia trachomatis , immunology , immune system , cd8 , pelvic inflammatory disease , antigen , pathology , medicine , gynecology
C hlamydia trachomatis is the most common bacterial sexually transmitted disease worldwide and leads to serious pathological sequelae in the upper genital tract ( UGT ) including pelvic inflammatory disease, ectopic pregnancy, and infertility. Several components of the host immune responses have been shown to contribute to the UGT pathology following genital chlamydial infection. We have shown recently that CD 8 + T cells induce the chlamydial UGT pathology via the production of TNF ‐α. However, those studies did not determine whether the pathology is mediated by bystander or antigen‐specific CD 8 + T cells. In this study, we compared chlamydial clearance and UGT pathology in OT ‐1 transgenic mice and the corresponding C57 BL /6J wild‐type mice following primary intravaginal C hlamydia muridarum infection. All CD 8 + T cells in the OT ‐1 mice respond only to the O va 257‐264 peptide and are incapable of responding to other antigenic epitopes including those of C hlamydia . OT ‐1 mice displayed vaginal chlamydial clearance comparable to the wild‐type animals. However, both oviduct and uterine horn pathology were minimal in the OT ‐1 mice compared with the high degree of pathology observed in the wild‐type animals. These results strongly suggest that C hlamydia ‐specific, not bystander, CD 8 + T cells mediate the UGT pathological sequelae following genital chlamydial infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here